A new study published in Science Translational Medicine by researchers at The University of Texas MD Anderson Cancer Center ...
Ochsner Health is expanding its partnership with The University of Texas MD Anderson Cancer Center to Slidell Memorial Hospital, bringing one of the nation’s most advanced cancer treatment programs to ...
News-Medical.Net on MSN
Study reveals a therapeutic vulnerability in aggressive subtype of triple-negative breast cancer
A new study published today in Science Translational Medicine by researchers at The University of Texas MD Anderson Cancer ...
Rush MD Anderson Cancer Center is coming to Chicago. The new partnership marks University of Texas MD Anderson’s seventh hospital partnership across the U.S., and is expected to expand access to ...
Ochsner Health announced on Thursday it has entered a 10-year partnership with The University of Texas MD Anderson Cancer Center to provide local patients access to the same treatments and trials ...
Medical Device Network on MSN
Pulse Biosciences and MD Anderson to study nPulse for thyroid cancer
Pulse Biosciences has entered a research partnership with The University of Texas MD Anderson Cancer Center, US, to investigate the nPulse Vybrance Percutaneous Electrode System’s use in treating ...
New research found patients with certain head and neck cancers lived longer and experienced fewer side effects when treated ...
The Brief keeps Texas voters and political observers up to speed on the most essential coverage of their elected officials, the policies that shape their daily lives and the future of our great state.
11monon MSN
Why doesn’t MD Anderson accept Affordable Care Act insurance plans? The answer is complicated.
MD Anderson is one of the best cancer centers in the nation, offering cutting-edge treatments that attract patients from ...
The University of Texas MD Anderson Cancer Center in Houston and the University of Texas at Austin have launched a joint initiative, the Collaborative Accelerator for Transformative Research Endeavors ...
Collaboration supports co-development of RB-340, a HER-2 targeted CAR T- cell therapy with context-dependent and inducible down-regulation of PD-1, through Phase 2 HOUSTON & MENLO PARK, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results